Van ECK Associates Corp Increases Position in Repligen Co. (NASDAQ:RGEN)

Van ECK Associates Corp increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 0.9% during the second quarter, Holdings Channel reports. The institutional investor owned 45,185 shares of the biotechnology company’s stock after acquiring an additional 404 shares during the period. Van ECK Associates Corp’s holdings in Repligen were worth $5,696,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rothschild Investment LLC purchased a new stake in shares of Repligen during the 2nd quarter worth approximately $57,000. Legacy Advisors LLC raised its holdings in Repligen by 30.5% during the second quarter. Legacy Advisors LLC now owns 5,732 shares of the biotechnology company’s stock worth $723,000 after purchasing an additional 1,338 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Repligen during the second quarter worth $33,000. Sivik Global Healthcare LLC acquired a new stake in Repligen in the second quarter valued at $1,891,000. Finally, Conestoga Capital Advisors LLC increased its position in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 6.1 %

RGEN stock opened at $141.79 on Wednesday. The company has a 50 day moving average price of $142.06 and a two-hundred day moving average price of $159.79. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock has a market capitalization of $7.94 billion, a P/E ratio of 567.18, a PEG ratio of 5.39 and a beta of 0.94. Repligen Co. has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.53 earnings per share. As a group, sell-side analysts expect that Repligen Co. will post 1.45 EPS for the current year.

Insider Buying and Selling at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Anthony Hunt bought 2,000 shares of Repligen stock in a transaction that occurred on Friday, June 14th. The shares were purchased at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the acquisition, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on RGEN. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Finally, UBS Group lowered their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $188.38.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.